Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Alexandria Venture Investments

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 209
Average round size
info
The average size of a deal this fund participated in
$53M
Portfolio companies 170
Rounds per year 7.46
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 23
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science
Summary

We also calculated 3 valuable employees in our database.

The higher amount of exits for fund were in 2019. The real fund results show that this VC is 13 percentage points less often commits exit comparing to other companies. The fund is constantly included in 25-48 investment rounds annually. Opposing the other organizations, this Alexandria Venture Investments works on 17 percentage points less the average amount of lead investments. The typical startup value when the investment from Alexandria Venture Investments is more than 1 billion dollars. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top activity for fund was in 2018.

The usual cause for the fund is to invest in rounds with 7 partakers. Despite the Alexandria Venture Investments, startups are often financed by ARCH Venture Partners, 5AM Ventures, Alexandria Real Estate Equities. The meaningful sponsors for the fund in investment in the same round are Polaris Partners, OrbiMed, 5AM Ventures. In the next rounds fund is usually obtained by Tim Disney, The Duke of Bedford, Illumina Ventures.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Biotechnology, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, Epic Sciences, Codiak Biosciences.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Alexandria Venture Investments:
Typical Co-investors
Alexandria Venture Investments is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Alexandria Venture Investments:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Elo Life Systems

Biotechnology
Health Care
Nutrition
Wellness
$20M24 Jan 2024 Durham, North Carolina, United States

Tr1x

Biotechnology
Health Care
Life Science
Medical
$75M17 Jan 2024 La Jolla, California, United States

Tome Biosciences

Biotechnology
Genetics
Medical
$213M12 Dec 2023 Watertown, Massachusetts, United States

Ability biologics

Biotechnology
Life Science
$12M06 Dec 2023 Quebec, Quebec, Canada

Alto Neuroscience

Artificial Intelligence
Biopharma
Neuroscience
$45M21 Nov 2023 Los Altos, California, United States

Deka Biosciences

Biotechnology
Health Care
$20M28 Sep 2023 Washington, District of Columbia, United States

Arialys Therapeutics

Health Care
Medical
Therapeutics
$58M12 Sep 2023 La Jolla, California, United States

Georgiamune

Biotechnology
Health Care
Therapeutics
$75M09 Aug 2023 Gaithersburg, Maryland, United States

Solu Therapeutics

Biotechnology
Therapeutics
$31M01 Aug 2023 Boston, Massachusetts, United States
News
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

– ROME Therapeutics announced the completion of a $77m Series B financing round.
– The round was led by new investor Section 32 and included participation from Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments.
– ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
– ROME has identified multiple repeatome-derived targets and created an internal data science platform, called repeatomics, to analyze vast quantities of data available through the repeatome.

Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Alexandria Venture Investments?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 209
Average round size 53M
Rounds per year 7.46
Peak activity year 2021
Lead investments 7
Follow on index 0.17
Exits 23
Group Appearance index 0.99

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Elo Life Systems

Biotechnology
Health Care
Nutrition
Wellness
$20M24 Jan 2024 Durham, North Carolina, United States

Tr1x

Biotechnology
Health Care
Life Science
Medical
$75M17 Jan 2024 La Jolla, California, United States

Tome Biosciences

Biotechnology
Genetics
Medical
$213M12 Dec 2023 Watertown, Massachusetts, United States

Ability biologics

Biotechnology
Life Science
$12M06 Dec 2023 Quebec, Quebec, Canada

Alto Neuroscience

Artificial Intelligence
Biopharma
Neuroscience
$45M21 Nov 2023 Los Altos, California, United States

Deka Biosciences

Biotechnology
Health Care
$20M28 Sep 2023 Washington, District of Columbia, United States

Arialys Therapeutics

Health Care
Medical
Therapeutics
$58M12 Sep 2023 La Jolla, California, United States

Georgiamune

Biotechnology
Health Care
Therapeutics
$75M09 Aug 2023 Gaithersburg, Maryland, United States

Solu Therapeutics

Biotechnology
Therapeutics
$31M01 Aug 2023 Boston, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: